Approval of ACP’s Immunization Committee (IC) recommendations to support ACIP recommendations for use of the Moderna COVID-19 primary series for adults 18+ under the FDA’s BLA.

Approved by the Executive Committee of the Board of Regents on Feb. 15, 2022

Background:

Each year, the Advisory Committee on Immunization Practices (ACIP) reviews and publishes the recommended adult immunization schedule for adults aged 19 and older. In November 2021, the Executive Committee of the Board of Regents (ECBOR) approved support of the 2022 ACIP Recommended Immunization Schedule for Adults, which will be published in *Annals* in February 2022. The ECOBR has also voted to support ACIP recommendations for use of Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines under the FDA’s Emergency Use Authorization (EUA), additional dose of mRNA COVID-19 vaccine among immunocompromised people, Pfizer-BioNTech COVID-19 vaccine under the FDA’s BLA, and booster doses for designated age and risk groups.

On Friday, February 4, 2022, the ACIP met and voted to recommend the Moderna COVID-19 vaccine (two-dose primary series) to persons 18 years of age and older under the FDA’s Biologics License Application (BLA). Other uses of the Moderna COVID-19 vaccine (e.g., additional doses) remain authorized under the FDA’s EUA.

ACP’s Immunization Committee (IC) conducted a vote by email on February 8-10, 2022. All IC members, including Vidya Sundareshan, MD, FACP (Chair); Michael Bronze, MD, MACP; Jason Goldman, MD, FACP; Saba Hasan, MD, FACP; Josune Iglesias, MD, FACP; Susan Lee, MD, FACP; and Kristin Mitchell, MD, FACP, voted unanimously to support the ACIP recommendations for the Moderna COVID-19 Vaccine.

The IC recommends that the ECOBR support the ACIP recommendations for use of the Moderna COVID-19 vaccine (Spikevax, two-dose primary series) for persons aged 18 years and older under the FDA’s BLA.